Stem cell IPO faces long odds

By Steven Bertoni

NEW YORK (Reuters) - The odds would seem to be against an initial public offering for a biotech company with no profits and no products on the market, but stem-cell company Aldagen evidently feels lucky.

The company registered with U.S. regulators on May 9 to publicly offer up to $80.5 million worth of common stock, even as the credit crunch dampens investor demand for IPOs.

"These are the worst capital markets for biotech in the last five years," said Steve Brozak, an analyst at WBB Securities. "Their technology is good, but it's a tough equity market."

Aldagen has extra difficulties, too -- it is working on drugs that involve stem cells, which have proven to be a difficult part of the biotech market to navigate. Chief Operating Officer Ed Field declined to comment.

"There has never been a small stem-cell company that has issued an IPO and then been successful in bringing products to market," said Amy Stevens, an analyst at the Susquehanna Financial Group. "It's completely uncharted waters and that's the highest risk associated with the companies."

These waters have made many investors seasick as the majority of publicly listed stem cell shares have suffered heavy declines.

StemCells Inc's (STEM.O: Quote, Profile, Research, Stock Buzz) shares have dropped more than 40 percent over the past year and shares of Aastrom Biosciences Inc (ASTM.O: Quote, Profile, Research, Stock Buzz) have fallen more than 70 percent.

Neuralstem Inc (CUR.A: Quote, Profile, Research, Stock Buzz) and NeoStem Inc (NBS.A: Quote, Profile, Research, Stock Buzz) have plunged more than 47 percent and 69 percent respectively since their August debuts on the American Stock Exchange. And BioHeart Inc (BHRT.O: Quote, Profile, Research, Stock Buzz), which went public in February, has lost over a third of its market value since its first day of trading.